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Abstract
Background: Authors and collaborators have continued
clinical research for Low Carbohydrate Diet (LCD) and
Calorie Restriction Diet (CRD), glucose variability and M
value. We investigated patients with Type 2 Diabetes
Mellitus (T2DM) with positive Glutamic Acid Decarboxylase
Antibody (GADA).
Subjects and methods: Subjects were 12 patients with
T2DM showing positive GADA (group 1). They were given
CRD on day 1,2, and LCD on day 3-14. Daily profile of blood
glucose was measured each day, and data were calculated
to M value expressing average glucose and Mean Amplitude
of Glycemic Excursions (MAGE). Further, 12 T2DM cases
with negative GADA were recruited, who were age-, sex-
glucose-related data-matched (group 2).
Results: Data of group 1 were as follows: age 54.9 ± 14.3 yo,
HbA1c 7.1 ± 0.9%, average blood glucose and M value on
day 2 vs 4 were 187 (157-255) vs 145 (114-172), 76.9
(45.9-278) vs 27.2 (19.3-83.5), respectively. In group 2, M
value on day 2 vs 4 were 69.9 (37.8-149) vs 5.8 (3.5-13.3),
respectively. Group 1 showed insufficient decreased glucose
in M value.
Discussion and conclusion: These results suggested that
cases with positive GADA would have insufficient insulin
secretion in response to LCD, and may lead to Slowly
Progressive Insulin-Dependent Diabetes Mellitus (SPIDDM)
status in the future.
Keywords: Glutamic acid decarboxylase antibody (GADA);
Slowly-progressive type 1 diabetes (SPIDDM); Glucose
variability Type 2 diabetes mellitus (T2DM); M value Low
Carbohydrate Diet (LCD)
Abbreviations: GADA: Glutamic Acid Decarboxylase
Antibody; MAGE: Mean Amplitude of Glycemic Excursions ;
SPIDDM: Slowly-Progressive Type 1 Diabetes; T2DM: Type 2
Diabetes Mellitus; LCD: Low Carbohydrate Diet; CRD: Calorie
Restriction Diet; HOMA-R: Homeostasis Model Assessment
of Insulin Resistance; HOMA-β: Homeostasis Model
Assessment of β Cell Function
Introduction
Diabetes has caused various influences to diabetic patients
with microvascular and macrovascular complications, and with
their Activities Daily Living (ADL) and Quality of Life (QOL) [1].
Furthermore, diabetes has been recently one of the crucial
medical problems worldwide. The number of the diabetic
patients has been increasing in both of developed and
developing countries. Then, the diagnosis and treatment for
diabetes has been crucial in the light of social and economic
aspects [2].
Diabetes has some categories including Type 1 Diabetes
Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM) and others.
As recent topic, there is a subtype between T1DM and T2M,
which has been in focus from clinical and immunological points
of view. It is necessary for careful evaluation, treatment and
following up for years.
T1DM has been classified into 2 types due to the guidelines of
the World Health Organization (WHO) and the American
Diabetes Association (ADA) in European and North American
region. They include i) Autoimmune diabetes (type 1A) and ii)
Idiopathic diabetes (type 1B) [3]. Among them, type 1A is
characterized for its presence of autoantibodies at the onset of
hyperglycemia, such as Glutamic Acid Decarboxylase Antibody
(GADA) and anti-Insulinoma-Associated Antigen 2 (IA2) and
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others [4]. In contrast, type 1B has been known by the
dependence without the present evidence of autoimmunity [3].
On the other hand, in Japan, T1DM has been classified into
rather detail way by Japan Diabetes Association (JDA). There are
i) autoimmune, ii) idiopathic from the etiology aspect, and iii)
acute, iv) Slowly Progressive Insulin-Dependent Diabetes
Mellitus (SPIDDM), v) fulminant in the light of onset style from
clinical aspect [5]. Diabetic cases with SPIDDM usually do not
show ketosis or ketoacidosis at the onset, and either not require
insulin treatment in earlier years [6]. As for the diagnosis of
SPIDDM, there are positive results for GADA and/or some kinds
of Islet Cell Antibodies (ICAs) [7].
Concerning this type of diabetic pathophysiological situation,
it is called as SPIDDM in Japan and Latent Autoimmune Diabetes
in Adults (LADA) in Western countries [8]. SPIDDM has been
characteristic for its positive GADA and ICA. Patients with
SPIDDM usually show insulin independent condition at the onset
period in early years. However, within several years, the patient
would possibly become insulin-dependent because of gradually
impaired insulin secretion [9]. Consequently, clinical
manifestation of diabetic condition has been found in SPIDDM
and LADA.
For the patients with SPIDDM, T2DM and T1DM, the authors
have continued clinical diabetic research for long years.
Especially, we have reported comparative study of nutritional
therapy, such Calorie Restriction Diet (CRD) and Low
Carbohydrate Diet (LCD).
CRD had been the ordinary nutritional therapy way formerly.
However, Atkins and Bernstein initiated and developed LCD
during 1980-90’s in western countries [10,11]. Thus, LCD has
been gradually popular, and the efficacy of LCD for weight
reduction and glucose lowering has been reported and known
widely. As a result, LCD revealed predominant effects in
comparison with the Mediterranean and CRD in the Dietary
Intervention Randomized Controlled Trial (DIRECT) study [12,13].
There have been various discussion on CRD and LCD so far,
indicating clinically predominance of LCD [14,15].
In contrast, authors and co-workers have initiated LCD for the
first time in Japan [16]. Successively, we have developed three
types of simple application of LCD into clinical practice and
health care field, which are petite LCD, standard LCD, and super
LCD [17,18]. We have continued the proposal of Meal Tolerance
Test (MTT). We always give diabetic two kinds of nutritional
treatment which are CRD and LCD together. In similar way of
Insulinogenic Index (IGI) for 75 g Oral Glucose Tolerance Test
(OGTT), 70 g of carbohydrate in CRD can be enough applied for
the study of the delta ratio of insulin/glucose at 0-30 min [19].
Furthermore, daily profile of blood glucose has been studied
for CRD and LCD meals. These data were transformed into M
value that is a numerical value indicating both of average blood
glucose and Mean Amplitude Of Glycemic Excursions (MAGE).
Both factors always influence blood glucose variability in the
diabetic patients.
Combining the both research mentioned above together,
authors have studied the pathophysiology of patients with
SPIDDM and T2DM groups. In this study, we report the glucose
variability of SPIDDM and the compare several biomarkers in the
both groups.
Materials and Methods
In this study subjects enrolled were 24 patients with T2DM.
They were recently diagnosed for T2DM, and admitted to the
hospital. This is called as educational diabetic admission for 14
days, including the evaluation and treatment for diabetes.
Group 1 and 2
There are two groups of the subjects. Group 1 includes the
patient diagnosed as T2DM in addition to the positive result for
GADA. The presence of GADA would indicate the possibility of
SPIDDM. There were 12 patients which were categorized into
Group 1 (Table 1).
Table 1 Basal data of the subjects with positive GAD-Ab.
Group
Caluculation of








Sex (male/female) 4/8 4/8




HbA1c (%) 7.1 ± 0.9 7.3 (6.3-7.8)
Glucose (0 min)




mg/dL 187 ± 66.9
169
(131-237)










(day 4) (mag/dL) 147 ± 46.4
145
(114-172)
M value (day 2) 153 ± 148 76.5(45.9-278)
M value (day 4) 63.8 ± 74.5 27.2(19.3-83.5)
On the other hand, group 2 has 12 patients with T2DM.
Authors have a long experience of clinical practice and research
for lots of diabetic patients who received the same protocol
examination of the admission and investigation for 14 days.
From many patients, 12 patients were picked up who showed
the similar result of age, sex, HbA1c and average blood glucose
to those of 12 patients in group 1. In other words, age, sex and
data-matched 12 patients were recruited for group 2. The
outlines of group 1 and 2 were shown in Table 2.
Endocrinology and Metabolism: Open Access
Vol.3 No.1:115
2019
2 This article is available from: http://www.imedpub.com/endocrinology-metabolism-open-access/
GAD-Ab.




Sex (male/female) 4/8 4/8
Age (years old\imean
+SD)
54.9 ± 14.3 55.3 ±
15.7
(median (25%-75%)) 52.5 (46-69) 51.5
(43.5-69)
M value (day 2) (mean
± SD)
153 ± 148 123 ± 136
(median (25% - 75%)) 76.9(45.9-278) 69.9
(37.8-149
)
M value (day 4) (mean
± SD)
63.8 ± 74.5 11.1 ±
11.8
(median (25% - 75%)) 27.2(19.3-83.5) 5.8
(3.5-13.3)
Basal data
Each patient was admitted to the hospital. In the morning on
the next day after overnight fasting, blood samples were drawn
for the examination of basal biochemistry. They included
Complete Blood Count (CBC), liver and renal function test, blood
lipids such as triglyceride, HDL-C, LDL-C and so on. As for the
fundamental diabetic tests, preprandial and postprandial blood
glucose, HbA1c, Immuno Reactivity of Insulin (IRI), C-peptide,
Homeostasis Model Assessment of Insulin Resistance (HOMA-R),
Homeostatic Model Assessment Beta cell function (HOMA-β), M
value, GADA were measured for the basal data. The laboratory
measurement method for GADA was Enzyme Immuno-Assay
(EIA) (bridge method), in which the standard value is less than 5
U/mL.
CRD and LCD
The detail of the evaluation include several kinds of
examination. They include i) To investigate the diabetic
situation, ii) To study the daily profile of blood glucose, iii) To
apply two patterns of diet therapy including CRD and LCD, iv) to
check the responses of blood glucose and insulin secretion
against the loading of breakfast including 70 g of carbohydrate,
v) To compare the glucose variability by the calculation of the M
value that indicates the mean level of average blood glucose in a
day and MAGE.
Nutritional elements
Authors have continued clinical diabetic research using a
certain protocol. It has two kinds of diet, which are CRD and LCD.
CRD has given to the patients on day 1 and 2, which PFC ratio is
15: 25: 60 with 1400 kcal a day. This meal is the traditional
Japanese meal pattern that was recommended as a standard
diet from the Japan Diabetes Association (JDA) [20]. On the
other hand, LCD was given to the patients from day 3 to day 14.
We have three kinds of LCD, which are super-LCD, standard LCD,
petite LCD, including the carbohydrate ratio as 12%, 26%, 40%,
respectively. In our protocol, we applied super LCD with 1400
kcal/day providing from day 3 to day 14.
Lipids profile
In our protocol, lipids profiles such as triglyceride, HDL-C and
LDL-C were measured on day 2 and day 14. The blood samples
were withdrawn after overnight fasting. The data were
compared in order to investigate the effect of the meal of LCD
for 12 days.
Daily profile of glucose
The patients were studied for their daily profile of blood
glucose. For the measurement of blood glucose, 7 times check
per day was done, which were 08, 10, 12, 14, 17, 19 and 22 hour.
Daily profile of glucose was investigated on day 2 and day 4. As
to related nutritional therapy, meal on CR was served on day 1
and 2, and meal on LCD was served from day 3-14. Then, the
difference between day 2 and day 4 means the short beneficial
effect of LCD for only 2 days. After measuring blood glucose 7
times a day, the data was calculated into M value using the
calculation equation of the formula about M value [21,22].
M value
As one of the evaluation method for glucose variability, M
value has been known and applied for useful biomarker. The
meaning of M value have two aspects. One is the level of the
average blood glucose a day and another is the changing width
of the glucose swinging. The latter has been called the MAGE
[21-23]. Both are important markers which give various
hyperglycemic influence for diabetic patients.
Consequently, M value is shown as one numerical value which
means both levels of average glucose an MAGE. From the
mathematic way of calculation, M value has been indicated as
the equation of the logarithmic transformation. The medical
significance of M value in the clinical practice would be that it
can reveal the degree how far the glucose deviation is situated
from the ideal daily glucose profile in a day [22-24].
The actual calculation method of M value has three steps. At
first, there is a the basal equation, indicating M=MBS + MW.
Then M value shows the total value of MBS and MW. Secondly,
MW means the degree of fluctuation, by the calculation of
(maximum blood glucose−minimum glucose)/20. Thirdly, MBS
shows the mean level of MBSBS. When combining these three
steps together, MBSBS means the individual M-value, that is
calculated as (absolute value of [10×log (blood glucose level/
120)])3 [22-24].
There is clinically standard evaluation way for M value, for the
deviated glucose variability. As to the obtained results M value,
the standard normal range is <180, borderline range is 180 and
between 180 and 320, and abnormal range is 320 and more
than 320.
Endocrinology and Metabolism: Open Access
Vol.3 No.1:115
2019
© Under License of Creative Commons Attribution 3.0 License 3
Table 2 Comparision  of  gluc ose  v ariability in 2 gr oup s b y 
Statistical analysis
Obtained data in current study were revealed by mean and
standard deviation. In the case of some biomarkers, the results
were revealed by the average in median and the quartile values
of 25% and 75%. There are some biomarkers which are
described as the median and quartiles of 25% and 75%. When
evaluating the correlation among biomarkers, the Spearman test
was applied for the correlation coefficients in the analyses.
Furthermore, the computerized standard statistical tool has
been used for analyzing some statistical evaluation [25].
Ethical Consideration
Current study was fundamentally performed in compliance
with the ethical principles on the Declaration of Helsinki.
Further, additional commentary was conducted on the Ethical
Guidelines for Research in the medical field for Humans and in
accordance with the Good Clinical Practice (GCP). Those were
found associated with the ongoing consideration for the
protection of human rights. In addition, “Ethical Guidelines for
Epidemiology Research” was applied as an adequate guideline.
This was presented in Japan by the Ministry of Education,
Culture, Sports, Science and Technology and the Ministry of
Health, Labor and Welfare.
Author’s have established an ethical committee. Regarding
the discussion on the medical and ethical problems, professions
were medical doctor, nurse, pharmacist, nutritionist and other
experts in the legal specialty. As regard to the study, our
discussion has become appropriate and valid, with the
agreements. In the light of patient standpoint, the informed
consents and written document agreements have been taken
from all subjects. This study has been registered by National
University Hospital Council of Japan (ID: #R000031211).
Results
Fundamental data
In this study, 12 patients with T2DM were enrolled with
positive result for GADA. Their basal data were shown in Table 1.
Their data were described by mean ± SD, and median/quartile of
25%/75%. Average ages was 54.9 ± 14.3 years old. Average
HbA1c was 7.1 ± 0.9%, and median HbA1c value was 7.3%. On
the morning of day 2, patient had breakfast of CRD with 70 g of
carbohydrate. The levels of blood glucose of 0 min and 30 min
was 147 mg/dL and 187 mg/dL, respectively. The result of GADA
(U/mL) was 76.4 (60.4-102) (median (25%-75%)).
Daily profile of blood glucose
Average blood glucose in day 2 and day 4 was 194 ± 59.1
mg/dL and 147 ± 46.4 mg/dL, respectively (Table 1). Converting
the data of daily profile of blood glucose into M value, the
median level of M value in day 2 and day 4 was 76.9 and 27.2,
respectively (Table 1).
Comparison of groups
According to the detail data of 12 subjects in group 1,
adequate 12 subjects were enrolled for group 2 in the light of
age, sex, HbA1c and average glucose. The data in group 1 and 2
were summarized and compared in Table 2. In both groups,
there are similar results in age and M value on day 2. However,
there is remarkable difference of M value on day 4 between
group 1 and group 2 (Table 2).
Decreased glucose
Average blood glucose was measured in day 2 and day 4, and
the correlation between them is shown in Figure 1. In both
group, average blood glucose on day 2 were in the same level.
Average blood glucose on day 4 in group 1 was moderately
decreased (Figure 1a). Its regression curve was y=0.68 x+13.8.
On the other hand, average blood glucose on day 4 in group 2
was remarkably decreased (Figure 1). Its regression curve was
y=0.24x+88.3. Consequently, there is difference of decreased
blood value between group 1 and group 2.
Figure 1 Correlation of average blood glucose between day 2
and day 4. a) Patients with positive GADA (n=12). b) Patients
with negative GADA (n=12).
Decreased M value
M value was measured in day 2 and day 4, and the correlation
between them is shown in Figure 2. In both group, M value on
day 2 were in the same level. According to the data of M value
on day 4 in group 1, 9 cases showed moderately decreased, but
3 cases showed not so decreased (Figure 1). Its regression curve
was y=0.25x+25.6. In contrast, M value on day 4 in group 2 was
remarkably decreased in all 12 cases (Figure 1). Its regression
curve was y=0.07x+2.8. Consequently, there is large difference
of M value between group 1 and group 2.
Figure 2 Correlation of M value between day 2 and day 4. a)
patients with positive GADA (n=12). b) patients with negative
GADA (n=12).
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Discussion
According to the quartile analysis, 50% of the subjects in this
study were 46-63 years of age, 6.3%-7.8% of HbA1c value. It
seemed to be generally standard level and distribution. Subjects
were given a standard breakfast of CRD containing 70 g of
carbohydrate on the morning in day 2 [19]. This is one of the
MTT, and it induced increased blood glucose and insulin
secretion, which were sufficient responses in the light of clinical
study.
For MTT, a breakfast of 450 kcal was initially attempted as a
test meal. The ratio of the nutrients was PFC=15:35:50, and the
amount of carbohydrate was 56 g [26]. After that, a trial of high-
protein Boost-HP formula meal was made. It included 33 g of
carbohydrate, 15 g of protein and 6 g of fat [27].
As a standard test, 75 g of OGTT has been applied in the
clinical practice using 75 g of carbohydrate. Similarly, we have
continued MTT utilizing a breakfast containing 70 g of
carbohydrate as a standard diet by CRD [19]. In addition to blood
glucose, IRI and/or C-peptide against 70 g of carbohydrate have
been also examined. Clinically, IGI-carbo 70 has been proposed
and can be used in the clinical practice of diabetes in the future.
Among several biomarkers, GADA, M value (day 2) and M
value (day 4) showed larger standard deviation value compared
with the average value of the mean. In these factors, median
value and quartile values of 25%/75% would be beneficial and
useful for obtaining the general situation [28]. One of the reason
would be the logarithmic distribution of the data from these
factors.
Enrolled 12 subjects with positive GADA (group 1) and data-
matched 12 subjects with T2DM (group 2) are compared. Both
groups showed almost the same age, sex, blood glucose and M
value on day 2. However, M value on day 4 showed remarkable
difference between both groups. This result suggest that the
insulin secretion in group 1 may show less glucose-lowering
effect in response to LCD meal.
There were significant correlation of blood glucose between
day 2 and day 4, in group 1 (GADA positive) and group 2 (GADA
negative). The values of glucose on day 2 were almost the same
in both group. However, the values of glucose on day 4 were
higher in group 1.
According to the regression curves of both group, three
glucose value can be input as 150 mg/dL, 200 mg/dL, 250 mg/dL
as day 2. Estimated glucose on day 4 in group 1 vs group 2 would
be 117 mg/dL vs 124 mg/dL, 152 mg/dL vs 136 mg/dL and 186
mg/dL vs 148 mg/dL, respectively. Thus, glucose value was
higher in group 1 (GADA positive) than that in group 2 (GADA
negative).
Similar to average blood glucose, M value on day 2 showed
almost the same level in both groups. However, M value on day
4 in group 1 did not decrease so much as that in group 2.
Regarding the correlation of M value between day 2 and day, the
distribution was wider in group 1, and it was narrower in group
2. These results suggest that patients in group 1 would show
various responses for LCD intervention, and patients in group 2
would show satisfactory similar responses for LCD intervention
with narrow distribution.
Comparing the both correlation of average blood glucose and
M value, detail difference of glucose variability can be found in
M value study rather than glucose study [24]. It is due to the
characteristic point that M value reflects average blood glucose
and MAGE. Consequently, current study method including daily
profile of blood glucose, average glucose and M value can be
useful for investigating not only present glucose variability, but
also future prediction for insulin secretion or diabetic status.
As regard to T1DM and SPIDDM, there have been some
Diabetes-Associated Autoantibody (DAA) in the light of
immunological aspect. Most sensitive marker is GADA in T1DM
and SPIDDM [29,30]. In the case of younger patients with recent
diagnosis of T1DM, rather frequent antibodies are Insulin Auto-
Antibodies (IAA), protein tyrosine phosphatase IA-2 (IA-2A), and
islet-specific zinc transporter isoform 8 (ZnT8). In contrast, there
are rather less found for SPIDDM [30].
From the former medical reports, the prevalence for GADA in
normal population was about 0.5%–0.8% [31]. In reference,
T2DM without insulin therapy was 2%-6%, and T2DM with
insulin dependent situation later was 11%–15%. Due to these
data, GADA could be responsible for the onset of diabetes and
decreased function of insulin secretion [32,33].
SPIDDM has been believed to be from the destruction of beta-
cell by islet-cell autoimmunity, and it is gradually proceeded to
the level of an insulin-dependent situation for long years [34].
The evidence of GADA has been necessary for diagnosis of
SPIDDM, but there were some controversy about the GADA
assay method by Radioimmunoassay (RIA) or Enzyme-Linked
Immunosorbent Assay (ELISA) [34].
Several reports are found about the measurement system for
GADA [35]. There was actually GADA-RIA way applied for clinical
practice. If the results of the titers level were classified into high
group and low group, C-peptide value was 0.73 ng/mL and 0.68
ng/mL, respectively without significance [35]. In contrast, if the
results measured by GADA-ELISA were classified between
positive and negative, C-peptide value was 0.85 ng/mL and 2.60
ng/mL, respectively with significant difference. Consequently,
GADA-ELISA seems to be beneficial for suggesting decreased
ability of insulin secretion [35].
What is the detail pathophysiology of SPIDDM? Endogenous
insulin secretion is maintained in T2DM but it is almost
abolished in T1DM. Actually, however, slight insulin secretion is
observed in T1DM as measured by the ultrasensitive C-peptide
assay [36]. Clinical study for T1DM patients with a long diabetes
history revealed that endogenous insulin secretion was detected
in 80% of cases [37]. Even with these clinical data, the details of
sustained insulin secretion in T1DM are still unclarified [38].
Future development would be expected with the elucidation of
the pathological condition of SPIDDM
There was a nationwide survey for SPIDDM in Japan. It is
multi-center study for study genetic characteristics for SPIDDM
by the Japan Diabetes Society (JDS) [9]. Patients with SPIDDM
were classified into two groups, which are Non-Insulin-Requiring
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SPIDDM (NIR-SPIDDM) and Insulin-Requiring SPIDDM (IR-
SPIDDM). By comparing these two groups, NIR-SPIDDM revealed
as follows: i) Later onset of diabetes, ii) Higher body mass index,
iii) Longer history before diagnosis, iv) Rarer hyperglycemic
symptoms at onset, v) Higher level of C-peptide, LDL-cholesterol
and Triglyceride (TG) values compared to those of IR-SPIDDM.
From genetic point of view, NIR-SPIDDM revealed vi) Less
frequency of susceptible HLA-DRB1*04:05-DQB1*04:01 and vii)
Higher frequency of resistant HLA-DRB1*15:01-DQB1*06:02
haplotype [9].
There is a limitation for this report. For T2DM cases with
positive GADA, further evaluation of their background, other
autoantibodies or related biomarkers, correlations among some
biomarkers and so on would be required. More cases and detail
analyses will be needed in the future.
Conclusion
In summary, 12 patients of T2DM with positive GADA (group
1) received diabetic evaluation such as daily profile of blood
glucose for CRD and LCD, converted analysis of M value and
correlations among related biomarkers. Further, compared with
recruited 12 cases of T2DM with matching age and data (group
2), there are cases where the reduction of average blood glucose
by LCD is insufficient in group 1, suggesting the possibility of
progress to SPIDDM status. Further analyses would be continued
and expected for future research in this field.
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